



Correction for Han et al., “*In Vitro* Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir”

Bin Han,^a Bandita Parhy,^a Julia Lu,^a Eric Zhou,^a David Hsieh,^a Gregory Camus,^a Ross Martin,^a Evguenia S. Svarovskaia,^a Hongmei Mo,^a Hadas Dvory-Sobol^a

^aGilead Sciences, Inc., Foster City, California, USA

Volume 57, no. 4, e01844-18, 2019, <https://doi.org/10.1128/JCM.01844-18>. This article was published on 28 March 2019 with a byline lacking Julia Lu. The byline was updated in the version posted on 22 April 2020.

Citation Han B, Parhy B, Lu J, Zhou E, Hsieh D, Camus G, Martin R, Svarovskaia ES, Mo H, Dvory-Sobol H. 2020. Correction for Han et al., “*In vitro* susceptibility of hepatitis C virus genotype 1 through 6 clinical isolates to the pangenotypic NS3/4A inhibitor voxilaprevir.” *J Clin Microbiol* 58:e00857-20. <https://doi.org/10.1128/JCM.00857-20>.

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Hadas Dvory-Sobol, Hadas.Dvory-Sobol@Gilead.com.

Published 24 June 2020